EMERYVILLE, Calif.--(BUSINESS WIRE)--Scientists at KineMed, Inc., describe a new technique to track the effects of neurodegeneration on neuronal transport as measured by the kinetics of specific biomarkers in cerebrospinal fluid (CSF). These measures provide a powerful translational approach for developing novel therapies and can facilitate clinical trials for better treatments that modify the progression of diseases such as Parkinson’s disease, Alzheimer’s disease, Amyotrophic Lateral Sclerosis, and potentially Huntington’s disease.
